Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion with cystoid macular edema
|
Accession number;04A0241637
|
| Title;Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion with cystoid macular edema |
| Author;
OHASHI HIROKAZU
(Kyoto Univ., Graduate School of Medicine, JPN)
NISHIWAKI HIROKAZU
(Kyoto Univ., Graduate School of Medicine, JPN)
MIYAMOTO KAZUAKI
(Kyoto Univ., Graduate School of Medicine, JPN)
O HIDEYASU
(Kyoto Univ., Graduate School of Medicine, JPN)
MIYAMOTO NORIKO
(Kyoto Univ., Graduate School of Medicine, JPN)
MURAKAMI TOMOAKI
(Kyoto Univ., Graduate School of Medicine, JPN)
NAKANISHI HIDEO
(Kyoto Univ., Graduate School of Medicine, JPN)
TAKAGI HITOSHI
(Kyoto Univ., Graduate School of Medicine, JPN)
|
Journal Title;Japanese Journal of Clinical Ophthalmology
|
Journal Code:Z0515B
|
ISSN:0370-5579
|
|
VOL.58;NO.3;PAGE.289-294(2004)
|
| Figure&Table&Reference;FIG.7, REF.20 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;We treated 13 eyes of central retinal vein occlusion (CRVO) by intravitreal injection of tissue plasminogen activator. All the eyes had clinically significant cystoid macular edema. The interval between onset of CRVO and treatment averaged 1.3 month. The logMAR visual acuity averaged 1.19 before start of treatment, 0.84 after 1 month, 0.80 after 3 months, and 0.72 after 6 months. The differences were significant (p<0.01). The macular thickness, when expressed as .MU.m, averaged 928 before treatment, 288 after 1 month, 293 after 3 months, and 213 after 6 months. The differences were significant (p<0.01). Complications, including retinal detachment or vitreous hemorrhage, were consistently absent. The findings show that intravitreal injection of tissue plasminogen activator is easy and safe and that it promises to be effective to improve visual acuity and cystoid macular edema in CRVO. (author abst.) |
|
|
|
Related Articles;
|
|
